1 Min Read
Feb 14 (Reuters) - Roche Holding AG:
* ROCHE HOLDING AG - FDA GRANTS PRIORITY REVIEW FOR ROCHE’S MABTHERA/ RITUXAN (RITUXIMAB) FOR PEMPHIGUS VULGARIS Source text for Eikon: Further company coverage: (Reporting By Michael Shields)
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.